Evaxion presents three year efficacy data for EVX-01

Evaxion to Present Three-year Clinical Efficacy Data for Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2026 - Moomoo

Evaxion will present three-year clinical efficacy data for its personalized cancer vaccine, EVX-01, at the ESMO Congress 2026. The presentation focuses on long-term outcomes, offering investors insight into the durability of patient responses to this neoantigen-targeted therapy.